Survey of Bladder Cancer Patients Reveals Big Changes – Patients are Looking for Cysview® (hexaminolevulinate)
UroToday.com published the key results of a survey answered by 600 bladder cancer patients. The biggest take-aways were that, more than ever before, bladder cancer patients know about Blue Light Cystoscopy with Cysview and are selecting urologists and treatment facilities that offer it.
Important Safety Information About Cysview® (hexaminolevulinate HCl)
Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.